Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well over $8 last year. Buying a shit ton more
Nice to see it hold above a buck though....cmon Jeff....stranger things have happened.
Anyone interested in buying a bridge?
BTIG Thinks OncoSec Medical’s Stock is Going to Recover
https://www.tipranks.com/news/blurbs/btig-thinks-oncosec-medicals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Trying to get that buck !
Getting a little better ..
There was nothing a few months ago when it was trading at $8...I'm buying more
$ONCS All-time low. Waste of time and money. Can be said that Punit dropped the ball on multiple occasions by missing chances to have the company bought out. It can also be said that he didn't want to have the company bought out and preferred to let it wallow in slime and filth like it's doing now. Not sure if Dan wanted anything for the company, either.
Let me say this again: GL to those who think there's something here.
Trading below cash like so many other biotech stocks. I think tax loss selling must be playing a part in this.
$ONCS is under a buck and at a new multi-year low. GL to those thinking there's something here.
Buying up these .90s....thanks
2 analysts give this a BUY Rating and a $10 price tag. Ummm..No brainer here for a long hold.
I'm loaded at $1.29
And can it get back there ?
How the heck was this at $8 last year ?
It’s China partners who already own a lot of shares.
Which partner are you referring to?
$ONCS
Was board chairman not CEO, Dan left months against they are still searching for a CEO.
Personally I think their partner will be buying company pretty soon.
CEO steps dowñ....that can't be good
17M share float.....any news and this will blow a gasket ! Loading up
Buying a shit ton here $1.27-$1.32 range...
Start accumulating..... This will get legs.
Anyone who's been here for any length of time (I'm here 10+ years) could tell you that OncoSec is junk. News of the CEO leaving had more affect on the stock price than did news of a collaboration with Merck.
Welcome to bag holder land. GLTY.
$ONCS
Check out this site for insider info. You can also check for other filings.
https://www.sec.gov/edgar/browse/?CIK=0001444307
$ONCS
Long term? HA!! I've been here 10-11 years. GLTY!!
$ONCS
Insiders own a bunch ? Really can't find any good info
Bought more yesterday. Feel good about this one....long term.
OncoSec has always been like this. In the past, if there had been gains after good news, they weren't held for very long. Sometimes, the gains were lost the same day the news came out.
$ONCS
Good news comes out....and this thing goes to free fall...wtf....
Throwing another $10K at this....gotta pick up.
Well...it did get to $8 somehow !!!!
Like the news never happened.....wow
For as long as I've been holding a position in $ONCS, it could never hold a gain no matter what the news was. I really hope they can eventually get their sh!t together but, it's just pure junk at this point.
Can't hold a gain
Roughly 50M shares traded in the first hour blew the previous record daily total volume out of the water.
$ONCS
Take these low 4's. Dips. Imho.
$ONCS
You hit the nail - Merck name all over the trial along with enrollment open to worldwide are the big differences this time. It is my believe that the trial will be proceeded much faster this time. Only issue is how (actually we knows...) they will fund the trial.
Yes, the “collaboration” in the past was mainly just Merck providing Keytruda to OncoSec for their small trial. It appears Merck will have more involvement in this trial, however my concern is the length of time it will take to enroll 400 participants.
Past trials with TAVO have taken several years for just 30 patients. Hopefully with Merck’s involvement and the fact that it’s multinational, it will speed up the process. It will also help that OncoSec has fast track designation for melanoma.
We’ll see….
Weren't there collaborations with Merck when Punit was the CEO? Whatever happened to those? Did they vanish into oblivion? I hope this one is different. I wonder if this collaboration came about through the efforts of the new guy, the interim CEO. Let's see how it turns out.
There were never any collaborations under Dan, that I can recall, except for that COVID-19 vaccine project with that hospital in the Pacific NW. That, also, has disappeared into oblivion.
$ONCS
Still under 40M outstanding here ?
ONCS...$3.90...in the P/M on the A/H News...https://finance.yahoo.com/news/oncosec-enters-collaboration-agreement-merck-200100384.html ...OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO:tm: Combined with KEYTRUDA:registered: for Late-Stage Metastatic Melanoma ...:partying_face:
NEWS -- OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
Finally!!!! What we've been talking about last several years announced after market closed today.
https://ir.oncosec.com/press-releases/detail/2089/oncosec-enters-into-a-collaboration-agreement-with-merck
I admire your optimism re: good news but, yesterday's big red candle and heavy volume indicated more capitulation. Don't know his reason for doing so but, Dan bailed from a sinking ship, imo.
OncoSec will most likely be a tax write-off for me unless there's a genuine miracle to turn this around, maybe even some divine intervention. haha
$ONCS
Followers
|
436
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
48316
|
Created
|
03/15/11
|
Type
|
Free
|
Moderators |
Cancer is a debilitating and swift-moving disease. To reach those affected by it, we need to move just as swiftly, with innovative treatments that extend lives and respect the need for quality of life.
Our mission at OncoSec is to pioneer and refine new electroporation technologies that save lives and enhance quality of life for those whose
skin cancers cannot be treated effectively with conventional treatment approaches.
Built on the foundation of a fast-paced, challenging, and entrepreneurial environment, OncoSec is committed to bringing proven treatments to the market quickly so those suffering today can have hope
for tomorrow. We will accomplish our mission through our entrepreneurial, results-driven culture, our proprietary technologies, our superior manufacturing and operational excellence, and strong
commercial leadership that identifies and expands the markets for our products.
At every step, we will fulfill our responsibilities to our stakeholders: the patients, physicians, healthcare workers, shareholders and employees who depend on-and are an integral part of-OncoSec's
continued success.
General information about OncoSec Medical, Incorporated: http://www.otcmarkets.com/stock/ONCS/company-info
SEC filings for OncoSec Medical, Incorporated: http://www.otcmarkets.com/stock/ONCS/filings
Twitter feeds
OncoSec Medical: https://twitter.com/Oncosec
Punit Dhillon, CEO: https://twitter.com/PunitDhillon
Excellent video which includes an interview with a melanoma survivor and OncoSec's CEO Punit Dhillon: http://globalnews.ca/video/539117/melanoma-monday
Investor Presentation: http://oncosec.com/QR-Downloads/ONCS-Investor-Presentation.pdf
OncoSec Corporate Profile: http://oncosec.com/QR-Downloads/ONCS-Corporate-Profile.pdf
An informative and comprehensive description of what OncoSec does: http://content.stockpr.com/oncosec/media/3edbc526ab7184e1257fcbcac727954e.pdf
A Selection of Significant Press Releases (PRs)
All news items about OncoSec Medical, Inc., can be found here: http://www.otcmarkets.com/stock/ONCS/news and here: http://ir.oncosec.com/company-news
OncoSec Announces Positive Results from Phase II Trial of ImmunoPulse™ IL-12 in Merkel Cell Carcinoma (September 27, 2015)
http://ir.oncosec.com/press-releases/detail/1840/oncosec-announces-positive-results-from-phase-ii-trial-of
OncoSec Announces First Patient Enrolled in Phase II Clinical Trial Evaluating Combination of ImmunoPulse™ IL-12 and Anti-PD-1 Treatment (August 18, 2015)
http://ir.oncosec.com/press-releases/detail/1835/oncosec-announces-first-patient-enrolled-in-phase-ii
OncoSec Medical Issues Annual Letter To Shareholders (June 17, 2015)
http://ir.oncosec.com/press-releases/detail/1829/oncosec-medical-issues-annual-letter-to-shareholders
OncoSec Medical Enrolls First Patient in Squamous Cell Carcinoma of the Head and Neck Phase II Clinical Trial (June 16, 2015)
http://ir.oncosec.com/press-releases/detail/1828/oncosec-medical-enrolls-first-patient-in-squamous-cell
OncoSec Medical Set to Join Russell Microcap Index (June 15, 2015)
http://ir.oncosec.com/press-releases/detail/1827/oncosec-medical-set-to-join-russell-microcap-index
OncoSec Medical Announces Uplisting to The NASDAQ Stock Market LLC (May 27, 2015)
http://ir.oncosec.com/press-releases/detail/1821/oncosec-medical-announces-uplisting-to-the-nasdaq-stock
OncoSec Medical and Massachusetts General Hospital to Evaluate Efficacy of Intratumoral Delivery of DNA-Based Interleukin-12 (May 18, 2015)
http://ir.oncosec.com/press-releases/detail/1819/oncosec-medical-and-massachusetts-general-hospital-to
OncoSec Medical Announces FINRA Approval of Reverse Stock Split (May 15, 2015)
http://ir.oncosec.com/press-releases/detail/1818/oncosec-medical-announces-finra-approval-of-reverse-stock
OncoSec Medical Inc. and Heat Biologics, Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms (February 18, 2015)
http://ir.oncosec.com/company-news/detail/1764/oncosec-medical-inc-and-heat-biologics-inc-announce-collaboration-to-evaluate-combination-of-immunotherapy-platforms
OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse (December 9, 2014)
http://ir.oncosec.com/company-news/detail/1714/oncosec-medical-announces-new-phase-ii-trial-in-head-and-neck-cancer-using-immunopulse
UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment (November 25, 2014)
http://ir.oncosec.com/company-news/detail/1634/uc-san-francisco-and-oncosec-medical-collaborate-to-evaluate-investigational-combination-of-immunopulse-and-anti-pd-1-treatment
Click this link to view ONCS chart: http://stockcharts.com/h-sc/ui?s=ONCS&p=D&yr=0&mn=3&dy=0&id=p75914482749
Technology
IMMUNOPULSE uses the body's immune system to target and destroy both local and metastasized cancer cells.
Using the OMS system, DNA IL-12 (a plasmid DNA construct with instructions to produce the IL-12 protein) is delivered into the electroporated cells. Upon entry, the gene triggers each cell to produce and
secrete the IL-12 protein, which in turn identifies and eliminates cancerous cells as part of a natural immune response.
Introducing pro-inflammatory cytokine proteins into the body as a potential anti-cancer therapy has produced encouraging data. For example, interleukin-12 (IL-12) cytokine is a naturally occurring protein
that activates and increases the levels of circulating macrophages and cytotoxic T-cells. In turn, this activity eliminates both foreign organisms and emerging cancerous cells.
In the past, cytokines were not considered a viable anti-cancer therapy because toxic levels were required to achieve an effective dose. However, when cytokines are delivered using DNA and the
OMS system, effective results can be achieved with a significantly reduced dosage, making this a viable treatment for both local and metastatic melanoma.
Initial evidence suggests that this gene therapy has the potential to not only treat cancer cells in the target area, but to also trigger immune responses affecting remote cancer cells outside the direct
treatment area including distant lesions.
View the following video for a brief explanation of how OncoSec's methods work:
https://www.youtube.com/watch?v=CJ843Ra3cyE
ImmunoPulse has demonstrated both safety and efficacy in a Phase 1 clinical trial for metastatic melanoma. It is currently being advanced in a Phase 2 confirmatory study enrolling at six centers
throughout the US.
PHASE I METASTATIC MELANOMA HIGHLIGHTS:
-- 90% OF TREATED LESIONS DEMONSTRATED LOCAL CONTROL.
-- 53% OF PATIENTS WITH METASTATIC DISEASE SHOWED OBJECTIVE RESPONSE.
-- 16% OF PATIENTS SHOWED COMPLETE REGRESSION.
NeoPulse boosts the effectiveness of an anti-cancer drug to kill cancer cells while minimizing toxic side effects.
NeoPulse uses the OMS system to destroy cancer cells using less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug.
Traditionally, bleomycin must be administered by intravenous infusion. Because this method targets cancer cells inefficiently, high doses must be used and significant side effects are common.
Using NeoPulse to electroporate and directly target cancerous cells with bleomycin, an effective result can be achieved with 1/20th of a traditional chemotherapy dose. In fact, by opening the cell membrane, we can enhance the
drug's ability to kill tumor cells by a factor of as much as 4,000.
Intensifying an already powerful drug
Bleomycin is proven to destroy cancer cells by attacking their DNA via an apoptotic or "suicidal" mechanism. When administered to cancer cells directly through electroporation, the efficacy of bleomycin
is increased exponentially. Even more advantageous, the pores of treated cells close shortly after introduction of the drug, trapping it within. Tests show that electroporated cells retain more of the drug, and retain it for a
longer period, thereby increasing the effectiveness of the treatment.
Extensive pre-clinical and clinical data from Phase 1 through 4 clinical trials demonstrate NeoPulse is safe and highly effective in eradicating solid tumors, including melanoma, basal cell
carcinoma, squamous cell carcinoma, and liver and pancreatic cancers, with observable cancer cell destruction, better quality of life benefits, and swift healing of the wound site.
HEAD AND NECK CANCER HIGHLIGHTS:
US PHASE III
-- 90% SUCCESS IN KILLING LOCALLY RECURRENT OR SECONDARY PRIMARY TUMOR.
-- 8 MONTHS ON AVERAGE, PATIENTS WHO RECEIVED OUR TREATMENT LIVED 8 MONTHS (EQUAL TO SURGERY).
EUROPEAN PHASE IV
-- 94% SUCCESS IN KILLING LOCAL PRIMARY TUMORS WITHOUT ANY RECURRENCE (MONITORED FOR 8 MONTHS).
Approximately 70,000 new cases of melanoma will be diagnosed every year, and this number is increasing. Despite this cancer being the deadliest form of all skin cancers, there still
remain few treatment options for patients with advanced-stage disease.
Previous data from a Phase I study demonstrated that using ImmunoPulse in melanoma patients is safe and well tolerated. In addition, promising therapeutic outcomes were observed
in 53% of patients with metastaticdisease, demonstrating an objective response to this therapy.
A Phase II safety and efficacy trial using OMS electroporation to deliver DNA IL-12 in patients with late-stage metastatic melanoma (OMS-I100) is being conducted in collaboration with the University of
California San Francisco. This open-label, multi-center Phase II trial will enroll approximately 25 patients with advanced-stage, cutaneous, in-transit malignant melanoma. Trials are currently being
conducted at three centers across the United States.
Further information: http://clinicaltrials.gov/ct2/show/NCT01502293?term=clinical+trials+adil+daud&rank=2
Merkel cell carcinoma is a rare and deadly disease. Despite a mortality rate of 40%, treatment options for these patients are scarce. Because 80% of Merkel cell carcinomas are caused by an associated
viral infection (Merkel cell polyomavirus), it is believed that an efficient and targeted immunotherapy may be a potential therapeutic approach for this disease.
A Phase II safety and efficacy trial using OMS ElectroImmunotherapy to deliver DNA IL-12 in patients with local and metastatic Merkel cell carcinoma (OMS-I110) is being conducted in collaboration with the
University of Washington. This open-label, multi-center Phase II trial will enroll approximately 15 patients with Merkel cell carcinoma. Trials are currently being conducted at two centers in the United States.
Further information: http://www.clinicaltrials.gov/ct2/show/NCT01440816?term=merkel+cell+carcinoma&rank=3
Cutaneous t-cell lymphoma is a rare form of non-Hodgkin's lymphoma that affects T-cells of the immune system, resulting in immune dysfunction. Though not life-threatening, this disease has proven
difficult to treat, with current therapies unable to demonstrate long-term benefits.
As a disease of the immune system, cutaneous T-cell lymphoma may be responsive to immunotherapy, a treatment in which the immune system is stimulated to fight cancer and destroy infected cells.
Immunotherapy has the potential to provide safe and long-lasting treatment.
A Phase II safety and efficacy trial using ImmunoPulse to deliver DNA IL-12 (a gene that triggers cells to attack and eliminate cancerous cells) in patients with early and late stage cutaneous T-cell
lymphoma (OMS-I120) is being conducted in collaboration with the University of California San Francisco. This open-label, multi-center Phase II trial will enroll approximately 27 patients with cutaneous
T-cell lymphoma. Trials are currently being conducted at one center in the United States.
Further information: http://clinicaltrials.gov/ct2/show/NCT01579318?term=CTCL+UCSF&rank=1
7 Key Questions & Answers
For the first time, there is a more efficient and targeted method of delivering cancer-fighting drugs.
Using a brief electrical pulse, electroporation temporarily opens the pores of cancer cells, allowing us to deliver drugs directly into those cells. This way, we can dramatically reduce the drug
concentration required to achieve therapeutic results.
What is the market size for OncoSec's target indications?
Today, more than two million skin cancers are diagnosed each year in the US alone. Most are non-deadly cancers called basal cell carcinomas and squamous cell carcinomas. These can be treated with
surgery, but surgical intervention can result in damaging cosmetic or functional outcomes.
Skin cancers can also be highly lethal and difficult-sometimes even impossible-to treat using conventional methods. These cancers including melanoma, Merkel cell carcinoma, and cutaneous T-cell
lymphoma.
There are 125,000 new cases of melanoma diagnosed each year, and this number is increasing, especially among young adults ages 18-35. Treatments are toxic, debilitating, and not always effective.
There are also 3,000 new cases of cutaneous T-cell lymphoma and 1,500 new cases of Merkel-cell carcinoma diagnosed each year in the US. Instances of these cancers, too, are increasing, and there are
currently no treatments available for these patients.
OncoSec's electroporation technologies target these potentially lethal and hard-to-treat skin cancers that conventional therapies can't reach effectively.
OncoSec's therapies have shown significant improvements in response compared to currently approved therapies. Just as important, they have been shown to trigger significantly fewer or less-intense side effects compared
to conventional treatment, thereby improving patients' quality of life as well as their longevity.
NeoPulse is being developed to treat primary and recurrent cancers that have not yet spread to other parts of the body. For these types of cancers, surgery is a possible treatment, but one that can have detrimental
cosmetic and functional effects because of the healthy surrounding tissue that is often excised. As an alternative therapy, NeoPulse can target and kill cancer cells while keeping the surrounding healthy tissue intact. This results in a less-invasive treatment with improved outcomes. NeoPulse also has the potential to minimize the risk of recurrence compared to surgery, because the cancerous cells can be targeted and killed with greater precision.
If you are an investor, a medical professional, or a potential trial participant, we invite you to contact us to learn more.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |